Virpax Pharmaceuticals (VRPX)
OTHER OTC:VRPX
Top Page
Virpax Pharmaceuticals
(OTC:VRPX)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.01
▲(0.00% Upside)
Action:ReiteratedDate:12/30/25
The score is primarily constrained by very weak financial performance (no revenue, recurring losses, sharply higher 2024 losses and cash burn, and negative equity), which elevates financing and dilution risk. Technicals are also weak with the price below key moving averages, while valuation metrics provide little support due to non-meaningful P/E and no dividend yield data.
Positive Factors
Strategic Partnerships
Strategic partnerships and licensing agreements can provide a steady revenue stream and facilitate product development, enhancing long-term growth potential.
Negative Factors
Financial Instability
Negative equity and financial instability pose significant risks to operational continuity, requiring urgent strategic pivots or capital injections to sustain business operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic Partnerships
Strategic partnerships and licensing agreements can provide a steady revenue stream and facilitate product development, enhancing long-term growth potential.
Read all positive factors
Virpax Pharmaceuticals (VRPX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$621.00
Dividend YieldN/A
Average Volume (3M)2.23K
Price to Earnings (P/E)―
Beta (1Y)3.06
Revenue GrowthN/A
EPS Growth60.26%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,242,504
10 Day Avg. Volume1,988
30 Day Avg. Volume2,232
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-44.23
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-2.42K
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Virpax Pharmaceuticals Business Overview & Revenue Model
Company Description
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for centra...
How the Company Makes Money
Virpax Pharmaceuticals makes money through the development and commercialization of its proprietary drug delivery systems and pharmaceutical products. The company's revenue model includes licensing agreements with other pharmaceutical companies an...
Virpax Pharmaceuticals Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
8
Very Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -11.96M | -14.69M | 0.00 | 0.00 | 4.00K |
| Net Income | -12.07M | -15.19M | -21.46M | -12.15M | -4.49M |
Balance Sheet | |||||
| Total Assets | 1.56M | 9.63M | 19.67M | 39.57M | 465.41K |
| Cash, Cash Equivalents and Short-Term Investments | 1.51M | 9.14M | 19.00M | 36.84M | 54.80K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 1.57M |
| Total Liabilities | 2.47M | 7.69M | 3.09M | 2.09M | 4.68M |
| Stockholders Equity | -913.76K | 1.93M | 16.58M | 37.48M | -4.22M |
Cash Flow | |||||
| Free Cash Flow | -16.71B | -9.85M | -17.85M | -14.54M | -1.38M |
| Operating Cash Flow | -16.71B | -9.85M | -17.85M | -14.54M | -1.38M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 9.08B | 0.00 | 0.00 | 51.33M | 1.40M |
Virpax Pharmaceuticals Technical Analysis
Negative
0.01
Price Trends
0.01
Negative
0.02
Negative
0.08
Negative
Market Momentum
>-0.01
Negative
45.33
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VRPX, the sentiment is Negative. The current price of 0.01 is above the 20-day moving average (MA) of <0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.33 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VRPX.
Virpax Pharmaceuticals Risk Analysis
Virpax Pharmaceuticals disclosed 70 risk factors in its most recent earnings report. Virpax Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Virpax Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
VRPX
Virpax Pharmaceuticals
0.01
-0.23
-95.42%
SCNI
Scinai Immunotherapeutics
0.59
-1.61
-73.18%
ADTX
Aditxt
0.53
-2,602.99
-99.98%
CERO
CERo Therapeutics Holdings
0.03
-15.37
-99.79%
PBM
Psyence Biomedical
2.50
-20.02
-88.90%
CDT
CDT Equity
5.89
-3,204.11
-99.82%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.